The FDA approved a phase 3 trial for amezalpat with Tecentriq and Avastin in hepatocellular carcinoma treatment. Amezalpat targets tumor cells and modulates the tumor microenvironment, potentially ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company’s global Phase 3 ...
The Phase 3 portion of the Orbit study for UX143 shows progress and is on track for a final analysis by the end of the year, suggesting effective management of the clinical trial timeline. The Data ...
Vera Therapeutics, Inc. announced that its ORIGIN Phase 3 trial for atacicept, a treatment for immunoglobulin A nephropathy (IgAN), achieved its primary endpoint by demonstrating a significant ...
Ultragenyx and Mereo Biopharma are expecting to report results from two phase 3 trials for Osteogenesis Imperfecta (OI), commonly known as brittle bone disease, at the end of 2025. Earlier in July, ...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...
Cidara Therapeutics’ main value driver, CD388, recently achieved an impressive 76% protection in its Phase 2b trials. It also showed a compelling safety profile. In my view, CD388 now has a clear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results